Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis - Wikidata - wikimedia - TriplyDB

Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis

Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis

http://www.wikidata.org/entity/Q34529109

about

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis New anti-tuberculosis drugs and regimens: 2015 update Pipeline of drugs for related diseases: tuberculosis Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tubercu In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480 Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.TB and HIV Therapeutics: Pharmacology Research Priorities.World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.Diagnosis and management of TB in children: an update.The oxazolidinones: past, present, and future.The anti-tuberculosis agents under development and the challenges ahead.Synthetic investigational new drugs for the treatment of tuberculosis.Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates.Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.In vitro isolation and characterization of oxazolidinone resistant Mycobacterium tuberculosis.An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants.In vitro release kinetics of antituberculosis drugs from nanoparticles assessed using a modified dissolution apparatus.Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial.Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model

P2860

Q28478966-9E7FC144-D69D-4EA2-9BF2-621DC8DD0F08 Q28537839-5163F095-3B01-4AB9-9A4D-3D2162380909 Q28596775-2DFB2EFE-BB0C-4E76-BA0C-A461B9F2C0F4 Q28818217-7D125608-ECEF-4DEB-9327-EE8CB48D4286 Q30419537-EEAB63B9-0AAB-4D65-B785-53F6EB71273B Q33760793-440A1F9B-F076-42C7-8759-835AD9470AF1 Q33767602-0DEA2CA3-9452-4639-B9BD-555E52F9786A Q33798120-405DE8E9-CF9C-48DC-955A-6D2F4689C636 Q33798173-3D649739-CF67-4AB8-9FC7-033C145454DA Q34737298-2CDA61C2-A314-4583-82C7-193556CA4939 Q34922056-870BCE4E-8EFA-479E-9A4D-C8EBD5FAB95E Q36018542-C5135C2D-E92F-41D1-AADB-BFAA693E4AA5 Q36094215-E0652B03-3D5A-43B0-8DC8-03D14573BA43 Q36099838-7E0A77E4-85F7-40B3-862F-772C80CD8F0F Q36957270-B7C7B3F7-84EB-410C-828F-8AD5AC16C364 Q36969745-3B590E7A-2933-4AAF-BE0D-64DACDE81697 Q37023104-1CD96C6F-7434-4C37-92B6-7F9698B85349 Q37074826-5F66C73D-F5CB-4DB8-963B-B3A10167B622 Q37960565-33EA6781-BF8F-4B52-A58B-77E4BDEFA98F Q37970719-0D1EB89D-2341-4E66-804B-687C3AA7CEAB Q38617197-3C412644-BAD5-411C-9A9D-A687F9603906 Q38635790-18E4AD50-7C50-445D-A2A9-5CA91F39329B Q38929509-FDD8E5FA-0E91-4906-BFD2-15B3B8E10D02 Q40071545-9B268A5A-D014-4996-9579-C72BB130E3A3 Q40110014-24B1ACC1-874D-41FE-A775-B1E10E02954C Q40112585-CF8A4659-AB47-4F03-A3B9-E1883309C3D8 Q41789967-3F350707-9FF2-450D-9AC6-EE4BAB9556DA Q41842047-D9B94494-5554-4667-B5FF-54575EF30253 Q42715629-371945A3-9C28-4BAB-8FBD-397F77894BD2 Q48713291-32A57CCD-87F6-40C7-A16B-F92C46D6BEF3 Q53687059-0FD21481-12F2-4D1E-8CF9-9349D69DC4E4 Q53698038-67DC30A5-4414-4CD0-9F21-DC12AF02BA58 Q57929304-15B55EFE-2053-48F0-BAC1-E1DC3C471DA1

P2860

Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis

http://www.wikidata.org/entity/Q34529109

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Biomarker-assisted dose select ...... of PNU-100480 for tuberculosis

@ast

Biomarker-assisted dose select ...... of PNU-100480 for tuberculosis

@en

Biomarker-assisted dose select ...... of PNU-100480 for tuberculosis

@nl

type

label

Biomarker-assisted dose select ...... of PNU-100480 for tuberculosis

@ast

Biomarker-assisted dose select ...... of PNU-100480 for tuberculosis

@en

Biomarker-assisted dose select ...... of PNU-100480 for tuberculosis

@nl

prefLabel

Biomarker-assisted dose select ...... of PNU-100480 for tuberculosis

@ast

Biomarker-assisted dose select ...... of PNU-100480 for tuberculosis

@en

Biomarker-assisted dose select ...... of PNU-100480 for tuberculosis

@nl

P1433

Q34529109-30333F95-1AC3-4F75-8091-C86ADF3BFEFA

P1476

Q34529109-85F43AA6-41DA-4487-9EA6-72040AA4FE94

P2093

Q34529109-02673174-D57D-4AF3-B5A0-33C0BB70B56E

Q34529109-0D87EE24-E457-4ABE-9D83-7DD6A73ED071

Q34529109-23EB731E-0A9E-47F4-AD1D-9BCE951BCA31

Q34529109-4BF33D62-4253-4FD6-AAB0-CA92EEEED617

Q34529109-5B1AF3D3-B160-4E68-8811-6778E12BD625

Q34529109-B3B974F9-81DA-4898-9D29-3D626A2F8B7E

Q34529109-B8076EA3-636E-4D61-99FE-1241E492930C

Q34529109-BB526F0A-B4A1-4F7C-87A5-43DCB5C566FB

Q34529109-C8200D5F-F71E-4BBC-AD1F-DFB9CD8FDC65

Q34529109-CB2A64F6-23CC-4BA8-AC85-8E86CCE8FFEA

P2860

Q34529109-0160BF3E-FE2C-4AEB-9A8C-608206AF32B9

Q34529109-0552D4CC-B05A-495A-8D6B-18EFD5812354

Q34529109-2144BDED-216E-4F7D-845B-CAC9E3D1D38C

Q34529109-232486A7-9E02-43A9-8049-9FB2BA6A6661

Q34529109-2652CF20-C5B2-44AA-90DB-8D782CB896F0

Q34529109-2B25B210-C616-47FB-97B0-99075B9AD6EC

Q34529109-39588494-084F-4C98-809A-802415AF15EA

Q34529109-39D04BFB-E80F-4B7B-A80E-281E4F02EC6E

Q34529109-443CCB79-69E7-4F25-9307-75FCAAB2F701

Q34529109-569D9FA8-1243-4E39-959F-7726368E1D9B

P304

Q34529109-ADDCC535-3F92-407A-8D12-BC54C767D9B6

P31

Q34529109-48F3964A-A1B8-4CEB-BCFE-FCD2D58F3005

P356

Q34529109-60DE2999-85D9-4A4F-A380-CB003261E3D2

P407

Q34529109-D6DA91A3-ADE1-4191-995C-CE0301F03545

P433

Q34529109-F43F4BA5-9272-4572-8C72-E250D0015740

P478

Q34529109-6166172B-B9C5-44D0-9BFF-0BEC4D944762

P50

Q34529109-D27B9BE1-803B-4576-980D-30EBE69348A9

P577

Q34529109-71094C3D-0049-4274-81D4-149468E26951

P698

Q34529109-A4CC06B8-75B5-4B3F-A9E7-5EDD87650F90

P921

Q34529109-B5CA87F4-AFCF-45BC-BC0C-B21B4DD660C2

Q34529109-B70A2981-974B-4AED-A3B5-79FF8FD30173

P932

Q34529109-1FDF5BFB-C356-488E-B0B9-5F2937C9A5B7

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Biomarker-assisted dose select ...... of PNU-100480 for tuberculosis

@en

P2093

Annette Silvia

http://www.w3.org/2001/XMLSchema#string

Darcy Paige

http://www.w3.org/2001/XMLSchema#string

Gabriella Bedarida

http://www.w3.org/2001/XMLSchema#string

Lynn Ladutko

http://www.w3.org/2001/XMLSchema#string

Paul F Miller

http://www.w3.org/2001/XMLSchema#string

Robert S Wallis

http://www.w3.org/2001/XMLSchema#string

Sheldon Campbell

http://www.w3.org/2001/XMLSchema#string

Tong Zhu

http://www.w3.org/2001/XMLSchema#string

Vikas Kumar

http://www.w3.org/2001/XMLSchema#string

Wesley Jakubiec

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones

Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture

Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

The curious characteristics of pyrazinamide: a review

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model

Thrombocytopenia associated with linezolid therapy.

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases.

P304

567-574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01179-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Mark Mitton-Fry

P577

2010-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21078950

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3028776

http://www.w3.org/2001/XMLSchema#string